JN Medsys specializes in digital PCR technology, which offers reliable quantification of nucleic acids through a unique high-density chip-based system. This innovative platform features 40,000 partitions, allowing for high-resolution detection across six channels and the capability to perform 96 reactions simultaneously. The technology is designed to minimize sample loss to less than 5%, ensuring high accuracy and throughput in genomic analysis. The company's flagship product, the Clarity digital PCR system, was launched in 2016 and has since established JN Medsys as a leader in the field, providing essential tools for researchers and clinicians.

In addition to their digital PCR systems, JN Medsys offers a range of services including sample analysis, assay development, and clinical validation. They can analyze samples using their proprietary digital PCR assays or those provided by clients, and they also develop and validate custom assays for both digital PCR and qPCR applications. Furthermore, the company provides next-generation sequencing (NGS) services, demonstrating their commitment to supporting a wide array of genomic analysis needs. With a focus on user-friendly and affordable solutions, JN Medsys aims to enhance the capabilities of researchers and laboratories in the field of molecular biology.

Singapore

JN Medsys is a people-centered life science company driven by the desire to make complex genomic tools accessible to more people. Through a relentless commitment to innovation, we aim to deliver simplified solutions that achieve improved performance at better affordability.

The Clarity digital PCR is the epitome of this vision. It brings digital PCR analysis to the next level by significantly reducing its preparation time and simplifying its workflow. With digital PCR this fast and easy, the choice is now clear. Choose Clarity for your digital PCR needs.

JN Medsys

Company Details